Wegovy Pill Outperforms Shots in Weight Loss
PUBLISHED Oct 1, 2026, 3:27 AM ET
Read, Watch or Listen
A recent real‑world study presented at a medical meeting showed that patients who switched from Novo Nordisk’s Wegovy injections to the daily oral pill continued to lose weight, and in some cases lost more than those who remained on injections. The data, released by the Danish drugmaker, aim to reinforce its position against U.S. competitor Eli Lilly in the growing market for oral obesity treatments. The study followed a cohort of patients who had previously used the injectable form of the drug and then transitioned to the pill, tracking weight changes over several months. Results indicated a steady decline in body mass, with average reductions exceeding those observed in the injection group. These findings could influence prescribing habits and insurance coverage decisions, potentially expanding access to the oral formulation for patients seeking a less invasive option.
By Shahbaz A. | JQJO News
Timeline of Events
- Study results presented at medical meeting
News Intelligence
- Immediate US impact: Potential shift in prescribing patterns
- Possible long-term US impact: Broader insurance coverage for oral weight loss
- Most affected groups: Patients seeking less invasive weight loss
- Reader priority: Understanding treatment options
Coverage of Story:
From Left
No left-leaning sources found for this story.
From Center
Patients Switching to Novo Nordisk's Wegovy Pill From Shots Lose More Weight in Real-World Study
U.S. News & World Report CP24 Toronto MarketScreener Reuters Times of India STAT Medical Xpress Devdiscourse News-Medical.net NewsBytes The Indian Express Medical Xpress Medical XpressFrom Right
No right-leaning sources found for this story.
Comments